Summary of Vir Biotechnology Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus Areas**: Infectious diseases and oncology, utilizing the human immune system to combat diseases [3][4] Key Strategies and Developments - **Oncology Programs**: - Development of masked T-cell engagers for metastatic solid tumors, with three clinical stage programs [3] - Recent compelling data from the prostate cancer program (VIR-5500) presented at ASCO GU [5] - Ongoing registrational program in hepatitis delta with initial data expected by the end of the year [4] Prostate Cancer Program (VIR-5500) - **Clinical Data**: - Phase 1 trial involved late-stage metastatic prostate cancer patients, many with poor prognoses [5] - Notable patient case: 63-year-old male with extensive liver metastases showed total obliteration of lesions after 9 weeks of treatment [6] - Achieved 53% PSA 90s and 29% PSA 99s in patients treated with doses above 3,000 micrograms per kilogram [7][12] - **Safety Profile**: - Low levels of cytokine release syndrome (CRS) and off-tumor toxicity, indicating a favorable safety profile [11][12] Competitive Landscape - **Differentiation**: - VIR-5500's dual masking technology allows for targeted action in the tumor microenvironment, potentially setting it apart from competitors [10] - Initial focus on late-line therapy with plans to explore earlier lines of therapy in combination with enzalutamide [15][17] Partnership with Astellas - **Deal Highlights**: - 50-50 profit split in the U.S. and co-promotion agreement, aiming for rapid market entry [20] - Financial terms include $1.7 billion in milestones and royalties, with Astellas covering 60% of global development costs [21] Future Plans - **Clinical Trials**: - Plans to skip Phase 2 and move directly to pivotal trials for VIR-5500 next year [24] - Expansion cohorts to begin in Q2 2026 [24] Other Oncology Programs - **HER2 and EGFR Programs**: - HER2 program showed initial signs of activity with 50% tumor shrinkage in a small cohort [36] - EGFR program is in early stages of dose escalation, exploring multiple indications [43] Hepatitis Delta Program - **Efficacy Data**: - 66% of patients reached undetectable levels after 48 weeks; 90% after 96 weeks [48] - Combination regimen of antibody and siRNA shows significant efficacy compared to competitors [50] - **Market Position**: - Anticipation of increased awareness and diagnosis of hepatitis delta due to competitive landscape [49] Financial Position - **Cash Runway**: - Increased cash position with partnerships and financing, providing runway until Q2 2028 [56] - Focus on oncology and hepatitis delta as key priorities while exploring other programs [57] Market Perception - **Company Transformation**: - Transition from a COVID-focused company to an immuno-oncology company, with a strong vision and promising data supporting this shift [58]

Financial Data and Key Metrics Changes - The company reported a net loss of $438 million for 2025, an improvement from a net loss of $522 million in 2024, reflecting a reduction in losses [44] - R&D expenses decreased to $456 million in 2025 from $507 million in 2024, a reduction of 10% [44] - SG&A expenses decreased to $92 million in 2025 from $119 million in 2024, representing a 23% decrease [44] - The company started 2026 with approximately $782 million in cash, cash equivalents, and investments, not including the upfront cash and equity from the Astellas collaboration [45] Business Line Data and Key Metrics Changes - The collaboration with Astellas is expected to accelerate the development of VIR-5500, a T-cell engager for prostate cancer, which is the company's most advanced immuno-oncology asset [7][8] - The financial terms of the collaboration include a total potential of $1.7 billion in combined upfront and milestone payments, with a 50/50 profit-sharing arrangement in the U.S. [14][41] Market Data and Key Metrics Changes - Prostate cancer remains a significant global health burden, with one in eight men diagnosed in their lifetime and a five-year survival rate of only 30% for patients with metastatic castration-resistant prostate cancer (mCRPC) [9] - There are approximately 100,000 mCRPC patients in the U.S. and Europe, indicating a substantial and growing unmet need for novel solutions [9] Company Strategy and Development Direction - The strategic collaboration with Astellas aims to advance the global development and commercialization of VIR-5500, unlocking significant market opportunities while de-risking the pipeline of cancer immunotherapies [7][8] - The company plans to initiate dose expansion cohorts in late-line mCRPC monotherapy and combination therapies in the second quarter of 2026, with a focus on addressing high unmet needs in metastatic prostate cancer [39][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of VIR-5500, citing favorable safety and efficacy signals from the phase I clinical data [18][39] - The collaboration with Astellas is seen as a key enabler for rapid advancement and broader patient access to VIR-5500, enhancing the company's position in immuno-oncology [46][47] Other Important Information - The PRO-XTEN platform, which powers VIR-5500, is expected to unlock opportunities for developing next-generation T-cell engagers in solid tumors [8] - The company has developed seven preclinical programs and plans to progress to development candidate selection by early 2027 [46] Q&A Session Summary Question: Can you comment on the range of PSA responses seen by prior line of therapies, particularly with regard to prior radiotherapy? - Management noted strong PSA responses, particularly at higher doses, with one patient showing promising results post-radioligand treatment [54][55] Question: What are the next steps before moving to phase III with Astellas? - The company plans to enter expansion cohorts in Q2 2026, focusing on late-line mCRPC as monotherapy and combinations with enzalutamide [61][62] Question: How does the larger cohort of patients evaluated on VIR-5500 evolve the thinking about its positioning within the treatment paradigm? - Management indicated plans to address a broad range of patients, including late-line mCRPC and early-line combinations, highlighting the high unmet need in these populations [68] Question: Can you provide more information on the go-forward dose for VIR-5500? - The go-forward dose is expected to be in the range of 3,000 to 3,500 micrograms per kg, with no grade 3 CRS observed at these doses [79][80]